Merck (MRK) Cash from Financing Activities (2009 - 2026)
Merck (MRK) posted quarterly Cash from Financing Activities of -$3.0 billion for Q1 2026, up 48.2% year-over-year from -$2.0 billion in Q1 2025, and down 162.74% quarter-over-quarter from $4.8 billion in Q4 2025.
Merck (MRK) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Cash from Financing Activities for 18 consecutive years, with -$3.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 48.2% year-over-year to -$3.0 billion; the TTM figure through Mar 2026 stood at $852.0 million (up 108.54% YoY), while the FY2025 annual figure was -$1.9 billion, up 72.67% from the prior year.
- Cash from Financing Activities eased to -$3.0 billion in Q1 2026 per MRK's latest filing, from $4.8 billion in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $4.8 billion in Q4 2025 and bottomed at -$5.8 billion in Q1 2025.
- Historically, Cash from Financing Activities has averaged -$1.5 billion across 5 years, with a median of -$2.4 billion in 2024.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 311.48% — and 2025, when it plunged 392.43%.
- Merck's Cash from Financing Activities stood at -$1.6 billion in 2022, then plunged by 44.47% to -$2.2 billion in 2023, then slumped by 34.03% to -$3.0 billion in 2024, then soared by 257.89% to $4.8 billion in 2025, then slumped by 162.74% to -$3.0 billion in 2026.
- Business Quant data shows MRK's Cash from Financing Activities at -$3.0 billion in Q1 2026, $4.8 billion in Q4 2025, and $2.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -3.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -2.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Bn |
| Jun 30, 2026 | 1.76 Bn |
| Mar 31, 2026 | -2.98 Bn |
| Mar 31, 2026 | -2.98 Bn |
| Dec 31, 2025 | 4.75 Bn |
| Dec 31, 2025 | 4.75 Bn |
| Sep 30, 2025 | 2.64 Bn |
| Sep 30, 2025 | 2.64 Bn |
| Jun 30, 2025 | -3.56 Bn |
| Jun 30, 2025 | -3.56 Bn |
| Mar 31, 2025 | -5.76 Bn |
| Mar 31, 2025 | -5.76 Bn |
| Dec 31, 2024 | -3.01 Bn |
| Dec 31, 2024 | -3.01 Bn |
| Sep 30, 2024 | -2.43 Bn |
| Sep 30, 2024 | -2.43 Bn |
| Jun 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.22 Bn |
| Mar 31, 2024 | -2.81 Bn |
| Mar 31, 2024 | -2.81 Bn |